Managing Creativity and Discovery in Pharma and University, with an Example from Motor Neuron Disease
A small biotech has advanced a novel, debt-free drug into Phase II for motor neuron disease, spotlighting a rare success in a field where most efforts fail and patients face death within years.
Key takeaways
- •Motor neuron disease (MND, also known as ALS) remains fatal with no cure, but 2025 saw multiple breakthroughs in targeted therapies, including protein-clearing molecules and gene silencers that slow progression in models and early trials.
- •Recent advances highlight tensions between academic innovation and pharma's risk-averse pipelines, as independent operators demonstrate creative, low-cost paths to clinical stages amid rising funding for AI-driven and repurposed drugs.
- •Stakes are high: MND affects thousands annually with average survival of 2-5 years post-diagnosis, and accelerating discoveries could yield disease-modifying treatments, but failures in translation risk delaying hope for patients.
Innovation Amid Despair
Motor neuron disease (MND), or amyotrophic lateral sclerosis (ALS), progressively destroys motor neurons, leading to muscle weakness, paralysis, and death typically within two to five years of diagnosis. Affecting around 5,000 people in the UK and far more globally each year, it has long defied effective treatments, with approved drugs like riluzole offering only modest survival extensions.
The landscape shifted noticeably in 2025 and early 2026. Preclinical work produced promising results: a designer molecule from Australian researchers cleared toxic misfolded SOD1 proteins in cells and slowed symptoms in mice, while UK teams identified neuroprotective candidates like M102 that preserved muscle function in models. Triple-drug combinations proved far more effective than single agents in lab tests, and initiatives like the £7.5 million Longitude Prize on ALS launched to harness AI for faster discovery.
Clinical momentum built too. Tofersen's long-term data showed delayed progression and even stabilisation or improvement in some SOD1-mutation patients, reinforcing targeted approaches. New Phase I and II trials started for candidates like NRG5051, which inhibits mitochondrial pores, and others entered platforms like EXPERTS-ALS and HEALEY for rapid testing. Repurposing efforts gained traction, backed by charities and consortia addressing funding shortages for rare diseases.
A core tension lies in bridging university-led creativity with pharmaceutical execution. Academic discoveries often stall in translation due to high costs and regulatory hurdles, yet nimble biotechs have reached Phase II without debt by pursuing unconventional paths. This matters because most MND cases are sporadic and biologically heterogeneous, making broad-spectrum failures common while precision successes remain limited to genetic subsets.
Inaction carries stark costs: patients endure rapid decline with no options to halt it, healthcare systems bear heavy burdens, and scientific momentum risks stalling without sustained investment. Yet the convergence of better biomarkers, adaptive trials, and cross-sector collaboration signals a potential turning point.
Sources
- https://www.bps.ac.uk/events/event/?tx_sfeventmgt_pieventdetail%5Baction%5D=detail&tx_sfeventmgt_pieventdetail%5Bcontroller%5D=Event&tx_sfeventmgt_pieventdetail%5Bevent%5D=36&cHash=c16d591db9dfbd5c19c512172ad862c7
- https://www.uow.edu.au/media/2025/researchers-unveil-potential-new-treatment-for-motor-neurone-disease.php
- https://sheffield.ac.uk/news/new-drug-candidate-offers-hope-slow-down-mnd-progress
- https://www.labiotech.eu/best-biotech/als-companies
- https://www.lifearc.org/2025/lifearc-joins-new-global-initiative-to-accelerate-drug-discovery-for-als-mnd-treatments
- https://www.mndassociation.org/research/latest-news
- https://www.ddw-online.com/disease-modifying-treatment-for-als-enters-phase-i-40159-202601
You might also like
- Mar 3TD Cowen’s 46th Annual Health Care Conference - Vertex Participation
- Mar 6What is dementia? (Dementia: what next? series)
- Apr 16Endometriosis Explained: Symptoms, Diagnosis, and Real-Life Management
- Apr 21Dementia Across the Spectrum Webinar Series – Mild to Moderate Dementia
- May 5Dementia Across the Spectrum Webinar Series – When it is not Alzheimer's Dementia: Thinking about the overlap with Frontotemporal Lobar dementia. Lewy Body Dementia (LBD) – Unique Features and Approac